Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma

Kwang Hyun Kim, Hyung Ho Lee, Young Eun Yoon, Joon Chae Na, Sook Young Kim, Young In Cho, Sung Joon Hong, WoongKyu Han

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

To determine the suitability of serum endocan (ESM-1) levels for diagnosing and monitoring renal cell carcinoma (RCC), we measure serum ESM-1 levels in 56 RCC patients who had undergone radical or partial nephrectomies and 56 age- and sex-matched healthy kidney donors. Measurements were made before and 1 month and 3 months after surgery. The areas under the curve (AUCs) were determined from receiver operating characteristic (ROC) analyses. RCC patients had higher mean serum ESM-1 levels than control subjects (0.59 ± 0.07 vs. 0.52 ± 0.08 ng/mL, P < 0.001), with an AUC of 0.721 (95% CI: 0.628-0.817). In patients with tumors larger than 2 cm (n = 40) and those with clear-cell histology (n = 44), the AUCs for ESM-1 were 0.771 and 0.721, respectively. In control subjects, serum ESM-1 levels were higher in older (> 50 years) individuals (P < 0.001). Among the study cohort, the AUCs for ESM-1 were 0.813 in individuals 50 years of age or younger (n = 55) and 0.637 in individuals older than 50 years (n = 57). In RCC patients, serum ESM-1 levels were reduced 1 month (P = 0.047) and 3 months (P = 0.009) after surgery. These results suggest serum ESM-1 can serve as a serologic biomarker for diagnosing and monitoring RCC, particularly in patients younger than 50 years.

Original languageEnglish
Pages (from-to)662-667
Number of pages6
JournalOncotarget
Volume9
Issue number1
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Renal Cell Carcinoma
Biomarkers
Serum
Area Under Curve
Nephrectomy
ROC Curve
Cohort Studies
Tissue Donors
Kidney

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Kim, Kwang Hyun ; Lee, Hyung Ho ; Yoon, Young Eun ; Na, Joon Chae ; Kim, Sook Young ; Cho, Young In ; Hong, Sung Joon ; Han, WoongKyu. / Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma. In: Oncotarget. 2018 ; Vol. 9, No. 1. pp. 662-667.
@article{735a05fba2f346a89bca82956687c175,
title = "Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma",
abstract = "To determine the suitability of serum endocan (ESM-1) levels for diagnosing and monitoring renal cell carcinoma (RCC), we measure serum ESM-1 levels in 56 RCC patients who had undergone radical or partial nephrectomies and 56 age- and sex-matched healthy kidney donors. Measurements were made before and 1 month and 3 months after surgery. The areas under the curve (AUCs) were determined from receiver operating characteristic (ROC) analyses. RCC patients had higher mean serum ESM-1 levels than control subjects (0.59 ± 0.07 vs. 0.52 ± 0.08 ng/mL, P < 0.001), with an AUC of 0.721 (95{\%} CI: 0.628-0.817). In patients with tumors larger than 2 cm (n = 40) and those with clear-cell histology (n = 44), the AUCs for ESM-1 were 0.771 and 0.721, respectively. In control subjects, serum ESM-1 levels were higher in older (> 50 years) individuals (P < 0.001). Among the study cohort, the AUCs for ESM-1 were 0.813 in individuals 50 years of age or younger (n = 55) and 0.637 in individuals older than 50 years (n = 57). In RCC patients, serum ESM-1 levels were reduced 1 month (P = 0.047) and 3 months (P = 0.009) after surgery. These results suggest serum ESM-1 can serve as a serologic biomarker for diagnosing and monitoring RCC, particularly in patients younger than 50 years.",
author = "Kim, {Kwang Hyun} and Lee, {Hyung Ho} and Yoon, {Young Eun} and Na, {Joon Chae} and Kim, {Sook Young} and Cho, {Young In} and Hong, {Sung Joon} and WoongKyu Han",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.23087",
language = "English",
volume = "9",
pages = "662--667",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "1",

}

Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma. / Kim, Kwang Hyun; Lee, Hyung Ho; Yoon, Young Eun; Na, Joon Chae; Kim, Sook Young; Cho, Young In; Hong, Sung Joon; Han, WoongKyu.

In: Oncotarget, Vol. 9, No. 1, 01.01.2018, p. 662-667.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma

AU - Kim, Kwang Hyun

AU - Lee, Hyung Ho

AU - Yoon, Young Eun

AU - Na, Joon Chae

AU - Kim, Sook Young

AU - Cho, Young In

AU - Hong, Sung Joon

AU - Han, WoongKyu

PY - 2018/1/1

Y1 - 2018/1/1

N2 - To determine the suitability of serum endocan (ESM-1) levels for diagnosing and monitoring renal cell carcinoma (RCC), we measure serum ESM-1 levels in 56 RCC patients who had undergone radical or partial nephrectomies and 56 age- and sex-matched healthy kidney donors. Measurements were made before and 1 month and 3 months after surgery. The areas under the curve (AUCs) were determined from receiver operating characteristic (ROC) analyses. RCC patients had higher mean serum ESM-1 levels than control subjects (0.59 ± 0.07 vs. 0.52 ± 0.08 ng/mL, P < 0.001), with an AUC of 0.721 (95% CI: 0.628-0.817). In patients with tumors larger than 2 cm (n = 40) and those with clear-cell histology (n = 44), the AUCs for ESM-1 were 0.771 and 0.721, respectively. In control subjects, serum ESM-1 levels were higher in older (> 50 years) individuals (P < 0.001). Among the study cohort, the AUCs for ESM-1 were 0.813 in individuals 50 years of age or younger (n = 55) and 0.637 in individuals older than 50 years (n = 57). In RCC patients, serum ESM-1 levels were reduced 1 month (P = 0.047) and 3 months (P = 0.009) after surgery. These results suggest serum ESM-1 can serve as a serologic biomarker for diagnosing and monitoring RCC, particularly in patients younger than 50 years.

AB - To determine the suitability of serum endocan (ESM-1) levels for diagnosing and monitoring renal cell carcinoma (RCC), we measure serum ESM-1 levels in 56 RCC patients who had undergone radical or partial nephrectomies and 56 age- and sex-matched healthy kidney donors. Measurements were made before and 1 month and 3 months after surgery. The areas under the curve (AUCs) were determined from receiver operating characteristic (ROC) analyses. RCC patients had higher mean serum ESM-1 levels than control subjects (0.59 ± 0.07 vs. 0.52 ± 0.08 ng/mL, P < 0.001), with an AUC of 0.721 (95% CI: 0.628-0.817). In patients with tumors larger than 2 cm (n = 40) and those with clear-cell histology (n = 44), the AUCs for ESM-1 were 0.771 and 0.721, respectively. In control subjects, serum ESM-1 levels were higher in older (> 50 years) individuals (P < 0.001). Among the study cohort, the AUCs for ESM-1 were 0.813 in individuals 50 years of age or younger (n = 55) and 0.637 in individuals older than 50 years (n = 57). In RCC patients, serum ESM-1 levels were reduced 1 month (P = 0.047) and 3 months (P = 0.009) after surgery. These results suggest serum ESM-1 can serve as a serologic biomarker for diagnosing and monitoring RCC, particularly in patients younger than 50 years.

UR - http://www.scopus.com/inward/record.url?scp=85040605957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040605957&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23087

DO - 10.18632/oncotarget.23087

M3 - Article

VL - 9

SP - 662

EP - 667

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 1

ER -